Metformin use associated with lower risk of joint replacement in people with type 2 diabetes

NewsGuard 100/100 Score

Osteoarthritis is a common chronic condition that usually causes joint pain and can be severe enough to require knee and hip replacements. In the United States, the number of total knee replacement (TKR) and total hip replacement (THR) surgeries is estimated to reach 572 000 per year by 2030. No medications are currently known to prevent or reverse osteoarthritis.

A team of researchers from China, Taiwan and Australia aimed to determine whether metformin use was associated with a lower risk of TKR or THR as evidence to date has been sparse and inconclusive. They analyzed data from 69 706 participants who received a diagnosis of type 2 diabetes in Taiwan between 2000 and 2012 and compared the risk of TKR and/or THR between people taking metformin and those not taking metformin. The mean age was 63 years and half were women. About 90% of total joint replacements were related to osteoarthritis.

"We found that metformin use in patients with type 2 diabetes mellitus was associated with a significantly reduced risk of joint replacement, suggesting a potential therapeutic effect of metformin in patients with osteoarthritis," writes Dr. Changhai Ding, Clinical Research Center of Zhujiang Hospital, Southern Medical University, Guangzhou, China, with coauthors.

The authors call for randomized controlled trials to determine if metformin use is effective in patients with osteoarthritis.

Source:
Journal reference:

Zhu, Z., et al. (2022) Metformin use and associated risk of total joint replacement in patients with type 2 diabetes: a population-based matched cohort study. CMAJ. doi.org/10.1503/cmaj.220952.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Landmark study sheds new light on the heterogeneity of type 2 diabetes